A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties

Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20–30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jie, Jiang, Liangfeng, Yang, Haodong, Deng, Lan, Meng, Xiaoqing, Ding, Jian, Yang, Sixing, Zhao, Le, Xu, Wei, Wang, Xiaolong, Zhu, Zhenping, Huang, Haomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896178/
https://www.ncbi.nlm.nih.gov/pubmed/35239451
http://dx.doi.org/10.1080/19420862.2022.2044435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896178/
https://www.ncbi.nlm.nih.gov/pubmed/35239451
http://dx.doi.org/10.1080/19420862.2022.2044435

Ejemplares similares